The Pragmatic Pioneer Protocol

Protocol overview

This protocol moves beyond the RCT-only tier to incorporate high-quality mechanistic research and early human trials where the signal is strong enough to be compelling. It's for people who understand they're operating on incomplete information — and are comfortable with that trade-off in exchange for potential early-mover advantage.

Time commitment: 6–9 hours. Complexity: Intermediate. Cost level: Moderate.

Who this is for

Informed, research-literate individuals who follow the science closely and are comfortable acting on strong mechanistic data before definitive long-term RCTs exist.

Core principles

• Start with everything in the Budget-Optimized Essentials protocol — this builds on top of RCT-proven foundations
• Accept that some interventions here may not pan out as hoped when long-term human data arrives
• Prioritize compounds with both strong mechanistic data AND at least early-phase human trials
• Monitor personal biomarkers to detect individual response
• Stay current with the literature — update the protocol as evidence evolves

Interventions from the rankings

• Urolithin A (mitochondrial)
• Quercetin (senolytic)
• Fisetin (senolytic)
• NMN/NR (NAD+ precursors)
• Lactoferrin

Supplement stack

• Urolithin A — 500–1,000mg daily: The gold standard of emerging longevity compounds: a human RCT published in Nature Metabolism showed improved muscle endurance and mitophagy markers. Strong mechanistic + early human data.
• Quercetin Phytosome — 1,000mg pulsed for 2 consecutive days every 1–3 months (paired with fisetin or dasatinib in trials): Quercetin alone has only weak human senolytic data; the published human signal comes from the dasatinib + quercetin (D+Q) combination (Hickson 2019, idiopathic pulmonary fibrosis; Justice 2019, diabetic kidney disease). Phytosome form improves bioavailability. Used as a senolytic adjuvant rather than a standalone daily antioxidant.
• Fisetin — 1,000–1,500mg for 2 consecutive days every 1–3 months: Mayo Clinic Phase 1/2 trials (AFFIRM-LITE, AFFIRM-AGE) are confirming pharmacokinetics and safety of intermittent high-dose fisetin; outcomes data still pending as of 2025. Preclinical evidence remains the strongest among natural senolytic candidates. Newer Kirkland-lab thinking favors quarterly rather than monthly pulses to allow senescent-cell repopulation between doses.
• NMN (250–500mg) or NR (300mg) — NMN 250–500mg or NR 300mg daily, morning: Both raise blood NAD+ in human PK studies. RCTs since 2022 (Yoshino, Yamashita, Igarashi, Yi) show modest improvements in muscle insulin sensitivity, walking endurance, blood pressure, and sleep — effect sizes are small and outcomes inconsistent. Note: FDA reclassified NMN out of dietary-supplement status in late 2022; legal/regulatory landscape remains in flux even though product is still widely sold.

Schedule overview